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making the historic comparisons even more challenging. Most experts
agree that the beneﬁts of OAC in RI are uncertain andmay be potentially
outweighed by bleeding hazards, while acknowledging several serious
gaps in evidence. Hence risks may outweigh beneﬁts among people
with low annual rates of stroke including those with early stages of RI,The optimal utilization of oral anticoagulants (OAC) in patients with
renal impairment (RI) represents an urgent, unmet, and yet unsolved
need with regard to the choice of agents, duration of treatment, and
potential dose/regimen adjustment (De Caterina et al., 2016; Verheugt
& Granger, 2015). Lack of any large randomized trials adequately
designed and powered speciﬁcally in such high-risk patients, absence
of the uniformed efﬁcacy and safety data reporting policy to the govern-
ment agencies, and endless overoptimistic publications based on post
hoc analyses of primary mega trials sometimes exaggerating beneﬁts
and hiding risks cloud the reality. In addition, triaging RI patients are
problematic due to ongoing kidney deterioration, and the fact that
such patients are simultaneously prone to both vascular occlusions
and bleeding (Blann & Lip, 2015). Despite signiﬁcant reductions in
morbidity and mortality over the last half-century, residual vascular
risk remains disproportionately high in the RI population. Our inability
to assess adequately the impact of OA on long-term outcomes in
these patients has been well recognized e.g. (De Caterina et al., 2016;
Verheugt & Granger, 2015; Blann & Lip, 2015; Ng et al., 2013).
Most of the evidence triagingOAC in RI patients consists of subgroup
analyses of trials, which in turn usually exclude patients with severe RI.
Not only are the sample sizes of most RI subgroups in such trials are
woefully small, but also the deﬁnitions of RI are variable making
cross-trial comparisons and deﬁnite conclusions difﬁcult. In addition,
many OAC trials deliberately avoided enrolling RI patients, especially
those with end stage renal failure or requiring dialysis or/and kidney
transplantation. To make the story even more complicated, RI patients
are prone to both thrombotic vascular occlusions and excess bleeding
makes the task of ﬁnding an optimal OAC regimen a variation of “mission
impossible” for such high-risk population. Regarding the impact of OAC
on efﬁcacy, the scant evidence suggests some positive impact on a
reduction of stroke but with uncertain effects on mortality and consis-
tently increased bleeding rates. Furthermore, deﬁnitions of events are
constantly changing especially with respect to bleeding, with ratesom.2016.04.013.
. This is an open access article undervarying greatly depending upon the scales/classiﬁcations used. In addi-
tion, trial durations and evolving standards of care are heterogeneous
especially in patients who do not have clinically-evident vascular
disease. Managing OA in such high-risk population is tricky since RI
patients experience increased hemostatic activation but attenuated
response to OA compared with patients without RI, even despite higher
dosages (Ng et al., 2013; Shen et al., 2012).
In this issue of EBioMedicine, Proietti and colleagues (Proietti et al.,
2016) analyzed pooleddatasets (n=3646) fromSPORTIF III and V trials
of warfarin-treated patients dependent on renal function. Diminished
creatinine clearance (b60 ml/min) was reported in 952 (26%) patients.
Overall, the time in therapeutic range (TTR) was higher in patients with
normal renal function compared to those with RI (p b 0.001). By logistic
regression, chronic atrial ﬁbrillation and male gender were associated
with TTR N 70%, whilst diabetes mellitus, aspirin use and RI were
inversely associated with TTR N 70%. On Cox analysis, RI was an inde-
pendent predictor for stroke (p = 0.006) and death (p b 0.001); while
TTR N 70% was independently associated with a lower risk of stroke
(p = 0.024), death (p = 0.001) and major bleeding (p = 0.001). The
combined SPORTIF warfarin data suggest that RI is highly prevalent
among patients with atrial ﬁbrillation, being a risk factor for stroke
and death. Adjusting for RI, good quality anticoagulation control
(TTR N 70%) was an independent predictor for lower risks of stroke,
death and major bleeding.
There are few important considerations yielded from these latest
elegant data. Importantly, patients with even mild RI experience much
more frequent vascular thrombotic events than patients with normal
kidney function. The index data are in full agreement that despite
huge differences among the trials with regard to exclusions, baseline
characteristics, randomization or enrollment patterns, and length of
followup, RI patients have consistently higher risks to experience primary
vascular endpoint event despite even a very liberal eGRF or creatinine
clearance of b60 ml/min cut-off to triage RI cohorts. Also, the RI patients
experience much more frequent bleeding events, especially those with
non-adjusted TTR. These two disturbing ﬁndings raise obvious concerns
that we may consider OAC dose/regimen downgrades in such patients,
the strategywhich is currently not recommended by the regulatory agen-
cies. The problem is that RI patients constitute no N10–15% of the entire
trial pool generating woefully small dataset(s) for each particular OAC.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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make such groups very small, usually in double-digit numbers hence
preventing quality analyses. These circumstances allow the regulatory
authorities to ignore such obvious shortcomings, or/and demand unbi-
ased risk assessment in RI patients receiving OAC. Indeed, the fact that
patients exhibited such poor outcomes in RI, (Proietti et al., 2016) we
should consider the advantage of non-Vitamin K antagonist oral antico-
agulants (NOACs) over warfarin. Indeed, there is some evidence (NICE
Guidance, n.d.; Halvorsen et al., 2014) that NOACs may be superior to
warfarin causing less bleeding complications. However, all OAC mega
trials suffer from massive double-digit incomplete follow-up rates,
challenging the quality of the analyzed datasets (Marciniak et al.,
2016). Overall, the current knowledge suggests no single superior
OAC choice with regard to their safety and efﬁcacy in patients with RI
(Harel et al., 2015). Further comparative randomized studies of differ-
ent OACs in patients with moderate and severe RI are urgently needed.
Disclosure
The author declared no conﬂicts of interest.
References
De Caterina, R., Husted, S., Wallentin, L., et al., 2016. Oral anticoagulants in coronary heart
disease (Section IV). Position paper of the ESC working group on thrombosis — task
force on anticoagulants in heart disease. Thromb. Haemost. 115, 685–711.Verheugt, F.W., Granger, C.B., 2015. Oral anticoagulants for stroke prevention in atrial
ﬁbrillation: current status, special situations, and unmet needs. Lancet 386 (9990),
303–310.
Blann, A.D., Lip, G.Y., 2015. Renal, endothelial function, warfarin management, and the
CHADS2, CHA2DS2VASc and HAS-BLED scores inpredicting MACE in AF. Thromb.
Haemost. 113, 1155–1157.
Ng, K.P., Edwards, N.C., Lip, G.Y., Townend, J.N., Ferro, C.J., 2013. Atrial ﬁbrillation in CKD:
balancing the risks and beneﬁts of anticoagulation. Am. J. Kidney Dis. 62, 615–632.
Shen, J.I., Turakhia, M.P., Winkelmayer, W.C., 2012. Anticoagulation for atrial ﬁbrillation in
patients on dialysis: are the beneﬁts worth the risks? Curr. Opin. Nephrol. Hypertens.
21, 600–606.
Proietti, M., Lane, D.A., Lip, G.Y.H., 2016. Chronic kidney disease, time in therapeutic
range and adverse clinical outcomes in anticoagulated patients with non-valvular
atrial ﬁbrillation: observations from the SPORTIF trials. EBioMedicine http://dx.doi.
org/10.1016/j.ebiom.2016.04.013 (http://www.sciencedirect.com/science/article/pii/
S2352396416301487).
NICE Guidance, d. Atrial ﬁbrillation: managementAvailable on-line @ https://www.nice.
org.uk/guidance/cg180 (assessed April 12, 2016).
Halvorsen, S., Atar, D., Yang, H., et al., 2014. Efﬁcacy and safety of apixaban comparedwith
warfarin according to age for stroke prevention in atrial ﬁbrillation: observations
from the ARISTOTLE trial. Eur. Heart J. 35, 1864–1872.
Marciniak, T.A., Cherepanov, V., Golukhova, E., Kim, M.H., Serebruany, V., 2016. Drug
discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern. Med.
176, 257–259.
Harel, Z., Sood, M.M., Perl, J., 2015. Comparison of novel oral anticoagulants versus
vitamin K antagonists in patients with chronic kidney disease. Curr. Opin. Nephrol.
Hypertens. 24, 183–192.
